Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMA401 |
| Synonyms | |
| Therapy Description |
IMA401 is a half-life extended T-cell engaging receptor (TCER) comprising a high-affinity T-cell receptor (TCR) domain targeting a HLA-A*02:01-presented MAGEA4/8 peptide, a T-cell recruiting antibody, and an Fc fragment, which potentially induces antitumor activity (Ann Oncol 35 (2024): S681-S682). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMA401 | IMA-401|IMA 401 | IMA401 is a half-life extended T-cell engaging receptor (TCER) comprising a high-affinity T-cell receptor (TCR) domain targeting a HLA-A*02:01-presented MAGEA4/8 peptide, a T-cell recruiting antibody, and an Fc fragment, which potentially induces antitumor activity (Ann Oncol 35 (2024): S681-S682). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05359445 | Phase I | IMA401 | IMA401 TCER in Recurrent and/or Refractory Solid Tumors | Recruiting | DEU | 0 |